CA2433866A1 - Traitement de troubles du systeme nerveux central au moyen d'antagonistes de la d-amino acide oxydase et de la d-aspartate oxydase - Google Patents

Traitement de troubles du systeme nerveux central au moyen d'antagonistes de la d-amino acide oxydase et de la d-aspartate oxydase Download PDF

Info

Publication number: CA2433866A1
Authority: CA; Canada
Prior art keywords: dao; substituted; alkyl; compound; polypeptide
Prior art date: 2001-01-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002433866A

Other languages

English (en)

Inventor

Daniel Cohen

Ilya Chumakov

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Biodevelopment SAS

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-16

Filing date

2002-01-15

Publication date

2002-08-29

2002-01-15 Application filed by Individual filed Critical Individual

2002-08-29 Publication of CA2433866A1 publication Critical patent/CA2433866A1/fr

Status Abandoned legal-status Critical Current

Links

238000011282 treatment Methods 0.000 title claims description 72
108010003989 D-amino-acid oxidase Proteins 0.000 title abstract description 304
108010070357 D-Aspartate Oxidase Proteins 0.000 title abstract description 179
102100039462 D-aspartate oxidase Human genes 0.000 title abstract description 176
239000005557 antagonist Substances 0.000 title abstract description 108
102100026908 D-amino-acid oxidase Human genes 0.000 title abstract 2
238000000034 method Methods 0.000 claims abstract description 266
150000001875 compounds Chemical class 0.000 claims abstract description 227
201000000980 schizophrenia Diseases 0.000 claims abstract description 149
208000020925 Bipolar disease Diseases 0.000 claims abstract description 116
208000015114 central nervous system disease Diseases 0.000 claims abstract description 96
108090000765 processed proteins & peptides Proteins 0.000 claims description 250
102000004196 processed proteins & peptides Human genes 0.000 claims description 248
229920001184 polypeptide Polymers 0.000 claims description 246
230000000694 effects Effects 0.000 claims description 137
150000001413 amino acids Chemical group 0.000 claims description 117
125000000217 alkyl group Chemical group 0.000 claims description 114
125000003729 nucleotide group Chemical group 0.000 claims description 107
239000012634 fragment Substances 0.000 claims description 106
239000002773 nucleotide Substances 0.000 claims description 105
150000007523 nucleic acids Chemical class 0.000 claims description 102
102000039446 nucleic acids Human genes 0.000 claims description 90
108020004707 nucleic acids Proteins 0.000 claims description 90
-1 D-Trp-methyl ester Chemical compound 0.000 claims description 63
125000000623 heterocyclic group Chemical group 0.000 claims description 61
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 61
229910052717 sulfur Inorganic materials 0.000 claims description 61
125000003342 alkenyl group Chemical group 0.000 claims description 52
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 52
230000000295 complement effect Effects 0.000 claims description 50
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 50
238000012360 testing method Methods 0.000 claims description 49
125000005842 heteroatom Chemical group 0.000 claims description 47
239000003550 marker Substances 0.000 claims description 47
229910052760 oxygen Inorganic materials 0.000 claims description 47
229910052757 nitrogen Inorganic materials 0.000 claims description 46
108700028369 Alleles Proteins 0.000 claims description 44
125000005843 halogen group Chemical group 0.000 claims description 41
150000003839 salts Chemical class 0.000 claims description 39
125000003545 alkoxy group Chemical group 0.000 claims description 38
229910052736 halogen Inorganic materials 0.000 claims description 38
239000003814 drug Substances 0.000 claims description 34
HRXJCQXGAHSUJC-UHFFFAOYSA-N 3,4-dehydrothiomorpholine-3-carboxylic acid Chemical compound OC(=O)C1=NCCSC1 HRXJCQXGAHSUJC-UHFFFAOYSA-N 0.000 claims description 30
150000002367 halogens Chemical class 0.000 claims description 29
125000003302 alkenyloxy group Chemical group 0.000 claims description 28
238000003556 assay Methods 0.000 claims description 28
230000002401 inhibitory effect Effects 0.000 claims description 26
230000015556 catabolic process Effects 0.000 claims description 23
238000006731 degradation reaction Methods 0.000 claims description 23
125000000547 substituted alkyl group Chemical group 0.000 claims description 23
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 22
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 22
229910052739 hydrogen Inorganic materials 0.000 claims description 21
150000008574 D-amino acids Chemical class 0.000 claims description 19
230000003647 oxidation Effects 0.000 claims description 19
238000007254 oxidation reaction Methods 0.000 claims description 19
UXWAJSLYHVAVKJ-UHFFFAOYSA-N 2-hydrazinyl-2-oxoacetic acid Chemical compound NNC(=O)C(O)=O UXWAJSLYHVAVKJ-UHFFFAOYSA-N 0.000 claims description 18
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 18
239000000523 sample Substances 0.000 claims description 18
239000011593 sulfur Substances 0.000 claims description 18
239000001257 hydrogen Substances 0.000 claims description 17
229910019142 PO4 Inorganic materials 0.000 claims description 16
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 16
239000010452 phosphate Substances 0.000 claims description 16
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 15
229920006395 saturated elastomer Polymers 0.000 claims description 14
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 12
125000005079 alkoxycarbonylmethyl group Chemical group 0.000 claims description 12
229910052799 carbon Inorganic materials 0.000 claims description 12
150000002825 nitriles Chemical class 0.000 claims description 12
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 11
238000001514 detection method Methods 0.000 claims description 10
CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 9
229960003151 mercaptamine Drugs 0.000 claims description 9
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 8
MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 claims description 8
229960001570 ademetionine Drugs 0.000 claims description 8
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
229910052698 phosphorus Inorganic materials 0.000 claims description 8
229910052710 silicon Inorganic materials 0.000 claims description 8
ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims description 7
238000003205 genotyping method Methods 0.000 claims description 7
YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 claims description 6
ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 claims description 6
WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 6
102000004190 Enzymes Human genes 0.000 claims description 6
108090000790 Enzymes Proteins 0.000 claims description 6
101100295738 Gallus gallus COR3 gene Proteins 0.000 claims description 6
ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 claims description 6
ZNXZGRMVNNHPCA-UHFFFAOYSA-N Pantetheine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-UHFFFAOYSA-N 0.000 claims description 6
125000003118 aryl group Chemical group 0.000 claims description 6
238000006243 chemical reaction Methods 0.000 claims description 6
125000004093 cyano group Chemical group *C#N 0.000 claims description 6
238000009396 hybridization Methods 0.000 claims description 6
ZNXZGRMVNNHPCA-VIFPVBQESA-N pantetheine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS ZNXZGRMVNNHPCA-VIFPVBQESA-N 0.000 claims description 6
IGBAFIMATACJON-UHFFFAOYSA-N 1,4-thiazepane-3,5-dicarboxylic acid Chemical compound OC(=O)C1CCSCC(C(O)=O)N1 IGBAFIMATACJON-UHFFFAOYSA-N 0.000 claims description 5
DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 claims description 5
229930195711 D-Serine Natural products 0.000 claims description 5
ZDXPYRJPNDTMRX-GSVOUGTGSA-N D-glutamine Chemical compound OC(=O)[C@H](N)CCC(N)=O ZDXPYRJPNDTMRX-GSVOUGTGSA-N 0.000 claims description 5
GHSJKUNUIHUPDF-BYPYZUCNSA-N L-thialysine Chemical compound NCCSC[C@H](N)C(O)=O GHSJKUNUIHUPDF-BYPYZUCNSA-N 0.000 claims description 5
108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
239000012472 biological sample Substances 0.000 claims description 5
GHSJKUNUIHUPDF-UHFFFAOYSA-N s-(2-aminoethyl)-l-cysteine Chemical compound NCCSCC(N)C(O)=O GHSJKUNUIHUPDF-UHFFFAOYSA-N 0.000 claims description 5
MHRLWUPLSHYLOK-UHFFFAOYSA-N thiomorpholine-3,5-dicarboxylic acid Chemical compound OC(=O)C1CSCC(C(O)=O)N1 MHRLWUPLSHYLOK-UHFFFAOYSA-N 0.000 claims description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims description 4
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 4
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 4
HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims description 4
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 4
LRQKBLKVPFOOQJ-RXMQYKEDSA-N D-norleucine Chemical compound CCCC[C@@H](N)C(O)=O LRQKBLKVPFOOQJ-RXMQYKEDSA-N 0.000 claims description 4
AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 claims description 4
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 4
229910006069 SO3H Inorganic materials 0.000 claims description 4
125000002837 carbocyclic group Chemical group 0.000 claims description 4
PMMYEEVYMWASQN-QWWZWVQMSA-N cis-4-hydroxy-D-proline Chemical compound O[C@H]1C[NH2+][C@@H](C([O-])=O)C1 PMMYEEVYMWASQN-QWWZWVQMSA-N 0.000 claims description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
KTHDTJVBEPMMGL-GSVOUGTGSA-N n-acetylalanine Chemical compound OC(=O)[C@@H](C)NC(C)=O KTHDTJVBEPMMGL-GSVOUGTGSA-N 0.000 claims description 4
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
ATOPRCUIYMBWLH-UHFFFAOYSA-N thiomorpholine-2-carboxylic acid Chemical compound OC(=O)C1CNCCS1 ATOPRCUIYMBWLH-UHFFFAOYSA-N 0.000 claims description 4
AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 claims description 3
ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims description 3
FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims description 3
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 3
OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims description 3
KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 3
238000010171 animal model Methods 0.000 claims description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
XJUQJVUYGRTQGI-SCSAIBSYSA-N cystathionine ketimine Chemical compound OC(=O)[C@H]1CCSCC(C(O)=O)=N1 XJUQJVUYGRTQGI-SCSAIBSYSA-N 0.000 claims description 3
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
XIVVIYYWXOMYOD-UHFFFAOYSA-N lanthionine ketimine Chemical compound OC(=O)C1CSCC(C(O)=O)=N1 XIVVIYYWXOMYOD-UHFFFAOYSA-N 0.000 claims description 3
125000001624 naphthyl group Chemical group 0.000 claims description 3
238000012163 sequencing technique Methods 0.000 claims description 3
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
101100097467 Arabidopsis thaliana SYD gene Proteins 0.000 claims description 2
IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical group [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims description 2
101100495925 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr3 gene Proteins 0.000 claims description 2
150000001717 carbocyclic compounds Chemical class 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 14
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 11
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
101150047265 COR2 gene Proteins 0.000 claims 3
101100467189 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) QCR2 gene Proteins 0.000 claims 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 325
208000028017 Psychotic disease Diseases 0.000 abstract description 38
102000004674 D-amino-acid oxidase Human genes 0.000 description 302
108091033319 polynucleotide Proteins 0.000 description 114
102000040430 polynucleotide Human genes 0.000 description 114
239000002157 polynucleotide Substances 0.000 description 114
229940024606 amino acid Drugs 0.000 description 113
235000001014 amino acid Nutrition 0.000 description 113
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 95
239000003112 inhibitor Substances 0.000 description 77
108090000623 proteins and genes Proteins 0.000 description 57
208000035475 disorder Diseases 0.000 description 55
208000024891 symptom Diseases 0.000 description 53
201000010099 disease Diseases 0.000 description 40
206010026749 Mania Diseases 0.000 description 33
229940079593 drug Drugs 0.000 description 26
210000004027 cell Anatomy 0.000 description 21
230000027455 binding Effects 0.000 description 20
230000001965 increasing effect Effects 0.000 description 20
239000002299 complementary DNA Substances 0.000 description 19
230000002068 genetic effect Effects 0.000 description 18
208000024714 major depressive disease Diseases 0.000 description 17
235000018102 proteins Nutrition 0.000 description 17
102000004169 proteins and genes Human genes 0.000 description 17
230000003993 interaction Effects 0.000 description 16
108091000042 riboflavin kinase Proteins 0.000 description 16
238000004458 analytical method Methods 0.000 description 15
239000002585 base Substances 0.000 description 14
230000002265 prevention Effects 0.000 description 14
208000024827 Alzheimer disease Diseases 0.000 description 13
239000000047 product Substances 0.000 description 13
101150046567 DAO gene Proteins 0.000 description 12
208000012902 Nervous system disease Diseases 0.000 description 12
230000003247 decreasing effect Effects 0.000 description 12
108020004999 messenger RNA Proteins 0.000 description 12
238000012216 screening Methods 0.000 description 12
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
108020004414 DNA Proteins 0.000 description 11
108700024394 Exon Proteins 0.000 description 11
241000282414 Homo sapiens Species 0.000 description 11
239000011714 flavin adenine dinucleotide Substances 0.000 description 11
239000000758 substrate Substances 0.000 description 11
210000001519 tissue Anatomy 0.000 description 11
208000019901 Anxiety disease Diseases 0.000 description 10
108010008292 L-Amino Acid Oxidase Proteins 0.000 description 10
102000007070 L-amino-acid oxidase Human genes 0.000 description 10
208000019022 Mood disease Diseases 0.000 description 10
HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 10
239000000935 antidepressant agent Substances 0.000 description 10
229940005513 antidepressants Drugs 0.000 description 10
210000000349 chromosome Anatomy 0.000 description 10
229960004170 clozapine Drugs 0.000 description 10
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 10
238000003745 diagnosis Methods 0.000 description 10
108010010779 glutamine-pyruvate aminotransferase Proteins 0.000 description 10
MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 10
239000000178 monomer Substances 0.000 description 10
230000036651 mood Effects 0.000 description 10
239000000126 substance Substances 0.000 description 10
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 9
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 9
230000003042 antagnostic effect Effects 0.000 description 9
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 9
230000002255 enzymatic effect Effects 0.000 description 9
238000000338 in vitro Methods 0.000 description 9
230000001603 reducing effect Effects 0.000 description 9
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 9
102100034976 Cystathionine beta-synthase Human genes 0.000 description 8
108010073644 Cystathionine beta-synthase Proteins 0.000 description 8
102100034545 FAD synthase region Human genes 0.000 description 8
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 8
102000048125 Riboflavin kinases Human genes 0.000 description 8
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 8
230000007423 decrease Effects 0.000 description 8
229940093632 flavin-adenine dinucleotide Drugs 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
102000054765 polymorphisms of proteins Human genes 0.000 description 8
239000013615 primer Substances 0.000 description 8
208000020016 psychiatric disease Diseases 0.000 description 8
230000001105 regulatory effect Effects 0.000 description 8
201000009032 substance abuse Diseases 0.000 description 8
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 8
WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 7
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 7
206010010144 Completed suicide Diseases 0.000 description 7
208000018737 Parkinson disease Diseases 0.000 description 7
208000008234 Tics Diseases 0.000 description 7
229960003767 alanine Drugs 0.000 description 7
208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 7
230000002860 competitive effect Effects 0.000 description 7
VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 7
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 7
229940088597 hormone Drugs 0.000 description 7
239000005556 hormone Substances 0.000 description 7
SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 7
BTNMPGBKDVTSJY-UHFFFAOYSA-N keto-phenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=CC=C1 BTNMPGBKDVTSJY-UHFFFAOYSA-N 0.000 description 7
239000002858 neurotransmitter agent Substances 0.000 description 7
239000012071 phase Substances 0.000 description 7
208000011117 substance-related disease Diseases 0.000 description 7
208000016686 tic disease Diseases 0.000 description 7
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
ARFHIAQFJWUCFH-IZZDOVSWSA-N Nifurtimox Chemical compound CC1CS(=O)(=O)CCN1\N=C\C1=CC=C([N+]([O-])=O)O1 ARFHIAQFJWUCFH-IZZDOVSWSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
235000004279 alanine Nutrition 0.000 description 6
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 6
208000028683 bipolar I disease Diseases 0.000 description 6
208000025307 bipolar depression Diseases 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
230000007812 deficiency Effects 0.000 description 6
235000019162 flavin adenine dinucleotide Nutrition 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
239000013038 irreversible inhibitor Substances 0.000 description 6
BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 6
229960003539 mitoguazone Drugs 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
230000000698 schizophrenic effect Effects 0.000 description 6
229940076279 serotonin Drugs 0.000 description 6
231100000736 substance abuse Toxicity 0.000 description 6
239000013598 vector Substances 0.000 description 6
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 5
DGYHPLMPMRKMPD-UHFFFAOYSA-N 2-azaniumylpent-4-ynoate Chemical compound OC(=O)C(N)CC#C DGYHPLMPMRKMPD-UHFFFAOYSA-N 0.000 description 5
SUFUDUDHGOHFHW-UHFFFAOYSA-N 2h-1,4-thiazine-3-carboxylic acid Chemical compound OC(=O)C1=NC=CSC1 SUFUDUDHGOHFHW-UHFFFAOYSA-N 0.000 description 5
101150002491 DDO gene Proteins 0.000 description 5
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
208000023105 Huntington disease Diseases 0.000 description 5
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
206010021030 Hypomania Diseases 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 description 5
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 5
DJICTQVUSNOZCH-MBNYWOFBSA-N [(2s,3r,4r)-5-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] phosphono hydrogen phosphate Chemical compound OP(=O)(O)OP(O)(=O)OC[C@H](O)[C@H](O)[C@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O DJICTQVUSNOZCH-MBNYWOFBSA-N 0.000 description 5
230000016571 aggressive behavior Effects 0.000 description 5
230000036506 anxiety Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
210000003169 central nervous system Anatomy 0.000 description 5
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 5
229960001076 chlorpromazine Drugs 0.000 description 5
230000034994 death Effects 0.000 description 5
231100000517 death Toxicity 0.000 description 5
238000011161 development Methods 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
230000006870 function Effects 0.000 description 5
125000001188 haloalkyl group Chemical group 0.000 description 5
210000003917 human chromosome Anatomy 0.000 description 5
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 5
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
230000033001 locomotion Effects 0.000 description 5
PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 5
JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 4
JCJMVSDVPRRNSU-UVEKSMONSA-N 2-[(e)-[(2e)-2-(diaminomethylidenehydrazinylidene)ethylidene]amino]guanidine Chemical compound NC(N)=N\N=C\C=N\N=C(N)N JCJMVSDVPRRNSU-UVEKSMONSA-N 0.000 description 4
239000001903 2-oxo-3-phenylpropanoic acid Substances 0.000 description 4
PKFNRZOFABOFSP-UHFFFAOYSA-N 3,4-dihydro-2h-1,4-thiazine-3,5-dicarboxylic acid Chemical compound OC(=O)C1CSC=C(C(O)=O)N1 PKFNRZOFABOFSP-UHFFFAOYSA-N 0.000 description 4
GOLXRNDWAUTYKT-UHFFFAOYSA-N 3-(1H-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)=CNC2=C1 GOLXRNDWAUTYKT-UHFFFAOYSA-N 0.000 description 4
RSTKLPZEZYGQPY-UHFFFAOYSA-N 3-(indol-3-yl)pyruvic acid Chemical compound C1=CC=C2C(CC(=O)C(=O)O)=CNC2=C1 RSTKLPZEZYGQPY-UHFFFAOYSA-N 0.000 description 4
PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 description 4
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 4
208000007848 Alcoholism Diseases 0.000 description 4
102000005680 D-aspartate oxidase Human genes 0.000 description 4
XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 4
206010012374 Depressed mood Diseases 0.000 description 4
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 4
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
208000001431 Psychomotor Agitation Diseases 0.000 description 4
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 4
208000000323 Tourette Syndrome Diseases 0.000 description 4
208000016620 Tourette disease Diseases 0.000 description 4
230000005856 abnormality Effects 0.000 description 4
DEDGUGJNLNLJSR-UHFFFAOYSA-N alpha-hydroxycinnamic acid Natural products OC(=O)C(O)=CC1=CC=CC=C1 DEDGUGJNLNLJSR-UHFFFAOYSA-N 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
230000001430 anti-depressive effect Effects 0.000 description 4
239000000164 antipsychotic agent Substances 0.000 description 4
238000013459 approach Methods 0.000 description 4
229940009098 aspartate Drugs 0.000 description 4
230000001364 causal effect Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
238000012512 characterization method Methods 0.000 description 4
230000002759 chromosomal effect Effects 0.000 description 4
229940104302 cytosine Drugs 0.000 description 4
238000012217 deletion Methods 0.000 description 4
230000037430 deletion Effects 0.000 description 4
229960003638 dopamine Drugs 0.000 description 4
FQYYIPZPELSLDK-UHFFFAOYSA-N ethyl pyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC=CC=N1 FQYYIPZPELSLDK-UHFFFAOYSA-N 0.000 description 4
125000001072 heteroaryl group Chemical group 0.000 description 4
BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 4
ZOAMBXDOGPRZLP-UHFFFAOYSA-N indole-3-acetamide Chemical compound C1=CC=C2C(CC(=O)N)=CNC2=C1 ZOAMBXDOGPRZLP-UHFFFAOYSA-N 0.000 description 4
KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
150000004658 ketimines Chemical class 0.000 description 4
208000015122 neurodegenerative disease Diseases 0.000 description 4
230000000926 neurological effect Effects 0.000 description 4
230000036963 noncompetitive effect Effects 0.000 description 4
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 4
239000002987 primer (paints) Substances 0.000 description 4
238000004393 prognosis Methods 0.000 description 4
230000000306 recurrent effect Effects 0.000 description 4
RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
229940113082 thymine Drugs 0.000 description 4
230000036967 uncompetitive effect Effects 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
ASVRUJBTDNHQMI-RXMQYKEDSA-N (2r)-2-(chloroamino)-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](NCl)C(O)=O ASVRUJBTDNHQMI-RXMQYKEDSA-N 0.000 description 3
DGYHPLMPMRKMPD-SCSAIBSYSA-N (2r)-2-azaniumylpent-4-ynoate Chemical compound OC(=O)[C@H](N)CC#C DGYHPLMPMRKMPD-SCSAIBSYSA-N 0.000 description 3
PGNYNCTUBKSHHL-PIKHSQJKSA-N (3s)-2,3-diaminobutanedioic acid Chemical compound OC(=O)C(N)[C@H](N)C(O)=O PGNYNCTUBKSHHL-PIKHSQJKSA-N 0.000 description 3
BNXNDZDKAOHDMR-UHFFFAOYSA-N 2-amino-4-oxopent-2-enoic acid Chemical compound CC(=O)C=C(N)C(O)=O BNXNDZDKAOHDMR-UHFFFAOYSA-N 0.000 description 3
WLGYAHUXLJQXLC-UHFFFAOYSA-N 2-aminopenta-2,4-dienoic acid Chemical compound OC(=O)C(N)=CC=C WLGYAHUXLJQXLC-UHFFFAOYSA-N 0.000 description 3
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 3
HKPXLDLEWBPXFW-UHFFFAOYSA-N 2-oxopent-3-ynoic acid Chemical compound CC#CC(=O)C(O)=O HKPXLDLEWBPXFW-UHFFFAOYSA-N 0.000 description 3
OXTNCQMOKLOUAM-UHFFFAOYSA-N 3-Oxoglutaric acid Chemical compound OC(=O)CC(=O)CC(O)=O OXTNCQMOKLOUAM-UHFFFAOYSA-N 0.000 description 3
QHKABHOOEWYVLI-UHFFFAOYSA-N 3-methyl-2-oxobutanoic acid Chemical compound CC(C)C(=O)C(O)=O QHKABHOOEWYVLI-UHFFFAOYSA-N 0.000 description 3
ALYNCZNDIQEVRV-UHFFFAOYSA-M 4-aminobenzoate Chemical compound NC1=CC=C(C([O-])=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-M 0.000 description 3
KKADPXVIOXHVKN-UHFFFAOYSA-N 4-hydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=C(O)C=C1 KKADPXVIOXHVKN-UHFFFAOYSA-N 0.000 description 3
BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical compound CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 3
JMHHECQPPFEVMU-UHFFFAOYSA-N 5-(dimethylamino)naphthalene-1-sulfonyl fluoride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(F)(=O)=O JMHHECQPPFEVMU-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
229930024421 Adenine Natural products 0.000 description 3
239000000275 Adrenocorticotropic Hormone Substances 0.000 description 3
201000010000 Agranulocytosis Diseases 0.000 description 3
239000004475 Arginine Substances 0.000 description 3
208000020706 Autistic disease Diseases 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
101800000414 Corticotropin Proteins 0.000 description 3
206010012289 Dementia Diseases 0.000 description 3
208000020401 Depressive disease Diseases 0.000 description 3
VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 3
108010057573 Flavoproteins Proteins 0.000 description 3
102000003983 Flavoproteins Human genes 0.000 description 3
206010020651 Hyperkinesia Diseases 0.000 description 3
208000000269 Hyperkinesis Diseases 0.000 description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
108060001084 Luciferase Proteins 0.000 description 3
239000005089 Luciferase Substances 0.000 description 3
208000036626 Mental retardation Diseases 0.000 description 3
HWGBHCRJGXAGEU-UHFFFAOYSA-N Methylthiouracil Chemical compound CC1=CC(=O)NC(=S)N1 HWGBHCRJGXAGEU-UHFFFAOYSA-N 0.000 description 3
229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 3
208000013716 Motor tics Diseases 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
102000004108 Neurotransmitter Receptors Human genes 0.000 description 3
108090000590 Neurotransmitter Receptors Proteins 0.000 description 3
108091034117 Oligonucleotide Proteins 0.000 description 3
208000027089 Parkinsonian disease Diseases 0.000 description 3
206010034010 Parkinsonism Diseases 0.000 description 3
206010036631 Presenile dementia Diseases 0.000 description 3
241000288906 Primates Species 0.000 description 3
102100024819 Prolactin Human genes 0.000 description 3
108010057464 Prolactin Proteins 0.000 description 3
206010037211 Psychomotor hyperactivity Diseases 0.000 description 3
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
108700008625 Reporter Genes Proteins 0.000 description 3
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
208000020186 Schizophreniform disease Diseases 0.000 description 3
206010039966 Senile dementia Diseases 0.000 description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
WIQBZDCJCRFGKA-UHFFFAOYSA-M Sodium-3-methyl-2-oxobutyrate Chemical compound [Na+].CC(C)C(=O)C([O-])=O WIQBZDCJCRFGKA-UHFFFAOYSA-M 0.000 description 3
206010043118 Tardive Dyskinesia Diseases 0.000 description 3
229940123445 Tricyclic antidepressant Drugs 0.000 description 3
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
KSUNRZWFIKXTKO-LIOBNPLQSA-N [(1s)-5,6-dichloro-2,3-dihydro-1h-inden-1-yl]-[(3r)-3-(pyrrolidin-1-ylmethyl)thiomorpholin-4-yl]methanone;hydrochloride Chemical compound Cl.C([C@@H]1CSCCN1C(=O)[C@H]1CCC=2C=C(C(=CC=21)Cl)Cl)N1CCCC1 KSUNRZWFIKXTKO-LIOBNPLQSA-N 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
230000009471 action Effects 0.000 description 3
229960000643 adenine Drugs 0.000 description 3
201000007930 alcohol dependence Diseases 0.000 description 3
WNNNWFKQCKFSDK-UHFFFAOYSA-N allylglycine Chemical compound OC(=O)C(N)CC=C WNNNWFKQCKFSDK-UHFFFAOYSA-N 0.000 description 3
230000008485 antagonism Effects 0.000 description 3
RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 3
230000000561 anti-psychotic effect Effects 0.000 description 3
239000000427 antigen Substances 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
239000002249 anxiolytic agent Substances 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
239000003693 atypical antipsychotic agent Substances 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
229960000258 corticotropin Drugs 0.000 description 3
OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 3
208000026725 cyclothymic disease Diseases 0.000 description 3
230000006735 deficit Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
206010013932 dyslexia Diseases 0.000 description 3
208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 3
239000012636 effector Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000007613 environmental effect Effects 0.000 description 3
208000015756 familial Alzheimer disease Diseases 0.000 description 3
230000003054 hormonal effect Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
229960004705 kojic acid Drugs 0.000 description 3
238000002372 labelling Methods 0.000 description 3
FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 3
235000011090 malic acid Nutrition 0.000 description 3
238000013507 mapping Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
239000002899 monoamine oxidase inhibitor Substances 0.000 description 3
229960002644 nifurtimox Drugs 0.000 description 3
YLACRFYIUQZNIV-UHFFFAOYSA-N o-(2,4-dinitrophenyl)hydroxylamine Chemical compound NOC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O YLACRFYIUQZNIV-UHFFFAOYSA-N 0.000 description 3
229960005017 olanzapine Drugs 0.000 description 3
238000007833 oxidative deamination reaction Methods 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
229950000688 phenothiazine Drugs 0.000 description 3
FAQJJMHZNSSFSM-UHFFFAOYSA-N phenylglyoxylic acid Chemical compound OC(=O)C(=O)C1=CC=CC=C1 FAQJJMHZNSSFSM-UHFFFAOYSA-N 0.000 description 3
SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 3
230000001817 pituitary effect Effects 0.000 description 3
239000000186 progesterone Substances 0.000 description 3
229960003387 progesterone Drugs 0.000 description 3
229940097325 prolactin Drugs 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
230000006798 recombination Effects 0.000 description 3
238000005215 recombination Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
229960001534 risperidone Drugs 0.000 description 3
208000022610 schizoaffective disease Diseases 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
150000003536 tetrazoles Chemical class 0.000 description 3
239000003029 tricyclic antidepressant agent Substances 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
PGNYNCTUBKSHHL-XIXRPRMCSA-N (2r,3s)-2,3-diaminobutanedioic acid Chemical compound OC(=O)[C@@H](N)[C@@H](N)C(O)=O PGNYNCTUBKSHHL-XIXRPRMCSA-N 0.000 description 2
NSGWUGKMTAEVPQ-UHFFFAOYSA-N (3-methylphenyl)methyl thiocyanate Chemical compound CC1=CC=CC(CSC#N)=C1 NSGWUGKMTAEVPQ-UHFFFAOYSA-N 0.000 description 2
VTESCYNPUGSWKG-UHFFFAOYSA-N (4-tert-butylphenyl)hydrazine;hydrochloride Chemical compound [Cl-].CC(C)(C)C1=CC=C(N[NH3+])C=C1 VTESCYNPUGSWKG-UHFFFAOYSA-N 0.000 description 2
BJEPYKJPYRNKOW-UWTATZPHSA-N (R)-malic acid Chemical compound OC(=O)[C@H](O)CC(O)=O BJEPYKJPYRNKOW-UWTATZPHSA-N 0.000 description 2
150000000192 1,4-thiazines Chemical class 0.000 description 2
LDVHYJKRIKBISQ-UHFFFAOYSA-N 1-(1h-indol-3-yl)propan-2-one Chemical compound C1=CC=C2C(CC(=O)C)=CNC2=C1 LDVHYJKRIKBISQ-UHFFFAOYSA-N 0.000 description 2
FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
LPIWIOBGUAPNQW-UHFFFAOYSA-N 1-chloro-1-nitroethane Chemical compound CC(Cl)[N+]([O-])=O LPIWIOBGUAPNQW-UHFFFAOYSA-N 0.000 description 2
TZSYLWAXZMNUJB-UHFFFAOYSA-N 1-methylpyridin-1-ium-3-carboxylic acid;chloride Chemical compound [Cl-].C[N+]1=CC=CC(C(O)=O)=C1 TZSYLWAXZMNUJB-UHFFFAOYSA-N 0.000 description 2
PGNYNCTUBKSHHL-UHFFFAOYSA-N 2,3-diaminobutanedioic acid Chemical compound OC(=O)C(N)C(N)C(O)=O PGNYNCTUBKSHHL-UHFFFAOYSA-N 0.000 description 2
MXWHMTNPTTVWDM-VEPASKNESA-N 2-[[(1e)-1-(diaminomethylidenehydrazinylidene)propan-2-ylidene]amino]guanidine Chemical compound NC(N)=NN=C(C)\C=N\N=C(N)N MXWHMTNPTTVWDM-VEPASKNESA-N 0.000 description 2
FIOHTMQGSFVHEZ-WUCPZUCCSA-N 2-[[(1s)-1-carboxyethyl]amino]propanoic acid Chemical compound OC(=O)C(C)N[C@@H](C)C(O)=O FIOHTMQGSFVHEZ-WUCPZUCCSA-N 0.000 description 2
GUWYZFXTOZCQRE-UHFFFAOYSA-N 2-[[2-(diaminomethylidenehydrazinylidene)-1-phenylethylidene]amino]guanidine Chemical compound NC(N)=NN=CC(=NN=C(N)N)C1=CC=CC=C1 GUWYZFXTOZCQRE-UHFFFAOYSA-N 0.000 description 2
QHFXORCWAQTTGH-UHFFFAOYSA-N 2-[[5-(dimethylamino)naphthalen-1-yl]sulfonylamino]acetic acid Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(=O)(=O)NCC(O)=O QHFXORCWAQTTGH-UHFFFAOYSA-N 0.000 description 2
UKVVXALGBMOHKE-UHFFFAOYSA-N 2-acetamidopent-4-ynoic acid Chemical compound CC(=O)NC(C(O)=O)CC#C UKVVXALGBMOHKE-UHFFFAOYSA-N 0.000 description 2
WFIFHOWQEJADPH-UHFFFAOYSA-N 2-chloro-4-(2-oxo-4-phenylpyrrolidin-1-yl)benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC=C1N1C(=O)CC(C=2C=CC=CC=2)C1 WFIFHOWQEJADPH-UHFFFAOYSA-N 0.000 description 2
JQPFYXFVUKHERX-UHFFFAOYSA-N 2-hydroxy-2-cyclohexen-1-one Natural products OC1=CCCCC1=O JQPFYXFVUKHERX-UHFFFAOYSA-N 0.000 description 2
KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
XFDUHJPVQKIXHO-UHFFFAOYSA-M 3-aminobenzoate Chemical compound NC1=CC=CC(C([O-])=O)=C1 XFDUHJPVQKIXHO-UHFFFAOYSA-M 0.000 description 2
229940086681 4-aminobenzoate Drugs 0.000 description 2
239000001142 4-methyl-2-oxopentanoic acid Substances 0.000 description 2
VHHNEBYEGKCBDS-UHFFFAOYSA-N 4-methylsulfanyl-2-oxopentanoic acid Chemical compound CSC(C)CC(=O)C(O)=O VHHNEBYEGKCBDS-UHFFFAOYSA-N 0.000 description 2
FWOMYZMCUZFCJV-UHFFFAOYSA-N 4-phenyl-1,4-thiazinane 1-oxide Chemical compound C1CS(=O)CCN1C1=CC=CC=C1 FWOMYZMCUZFCJV-UHFFFAOYSA-N 0.000 description 2
BZYHBWCVRKSWDB-ZETCQYMHSA-N 5-S-Cysteinyldopamine Chemical compound NCCC1=CC(O)=C(O)C(SC[C@H](N)C(O)=O)=C1 BZYHBWCVRKSWDB-ZETCQYMHSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
206010010071 Coma Diseases 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
UIKROCXWUNQSPJ-UHFFFAOYSA-N Cotinine Natural products C1CC(=O)N(C)C1C1=CC=CN=C1 UIKROCXWUNQSPJ-UHFFFAOYSA-N 0.000 description 2
239000003155 DNA primer Substances 0.000 description 2
206010011971 Decreased interest Diseases 0.000 description 2
206010012239 Delusion Diseases 0.000 description 2
206010054089 Depressive symptom Diseases 0.000 description 2
208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
206010016374 Feelings of worthlessness Diseases 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
206010018671 Grandiosity Diseases 0.000 description 2
208000004547 Hallucinations Diseases 0.000 description 2
206010019196 Head injury Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000889548 Homo sapiens Amiloride-sensitive amine oxidase [copper-containing] Proteins 0.000 description 2
101000983200 Homo sapiens D-amino-acid oxidase Proteins 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
VAFNMNRKDDAKRM-LLVKDONJSA-N Indole-3-acetyl-L-aspartic acid Natural products C1=CC=C2C(CC(=O)N[C@H](CC(=O)O)C(O)=O)=CNC2=C1 VAFNMNRKDDAKRM-LLVKDONJSA-N 0.000 description 2
NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 description 2
ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 2
150000008575 L-amino acids Chemical class 0.000 description 2
DGYHPLMPMRKMPD-BYPYZUCNSA-N L-propargylglycine Chemical compound OC(=O)[C@@H](N)CC#C DGYHPLMPMRKMPD-BYPYZUCNSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
208000009829 Lewy Body Disease Diseases 0.000 description 2
201000002832 Lewy body dementia Diseases 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
208000026072 Motor neurone disease Diseases 0.000 description 2
YDXXLJMIHMIOIF-UHFFFAOYSA-N N-(indol-3-ylacetyl)glycine Chemical compound C1=CC=C2C(CC(=O)NCC(=O)O)=CNC2=C1 YDXXLJMIHMIOIF-UHFFFAOYSA-N 0.000 description 2
FBDCJLXTUCMFLF-QMMMGPOBSA-N N-(indole-3-acetyl)-L-alanine Chemical compound C1=CC=C2C(CC(=O)N[C@@H](C)C(O)=O)=CNC2=C1 FBDCJLXTUCMFLF-QMMMGPOBSA-N 0.000 description 2
VAFNMNRKDDAKRM-NSHDSACASA-N N-(indole-3-acetyl)-L-aspartic acid Chemical compound C1=CC=C2C(CC(=O)N[C@@H](CC(=O)O)C(O)=O)=CNC2=C1 VAFNMNRKDDAKRM-NSHDSACASA-N 0.000 description 2
WXNXCEHXYPACJF-SSDOTTSWSA-N N-acetyl-D-leucine Chemical compound CC(C)C[C@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-SSDOTTSWSA-N 0.000 description 2
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
206010037213 Psychomotor retardation Diseases 0.000 description 2
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
208000030988 Schizoid Personality disease Diseases 0.000 description 2
208000024791 Schizotypal Personality disease Diseases 0.000 description 2
108091035242 Sequence-tagged site Proteins 0.000 description 2
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
239000012190 activator Substances 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
230000003281 allosteric effect Effects 0.000 description 2
229940125528 allosteric inhibitor Drugs 0.000 description 2
150000004716 alpha keto acids Chemical class 0.000 description 2
230000000049 anti-anxiety effect Effects 0.000 description 2
229940124604 anti-psychotic medication Drugs 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
229940041181 antineoplastic drug Drugs 0.000 description 2
229940005529 antipsychotics Drugs 0.000 description 2
230000036528 appetite Effects 0.000 description 2
235000019789 appetite Nutrition 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
230000008236 biological pathway Effects 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
150000001649 bromium compounds Chemical class 0.000 description 2
SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
206010007776 catatonia Diseases 0.000 description 2
238000000423 cell based assay Methods 0.000 description 2
206010008118 cerebral infarction Diseases 0.000 description 2
208000026106 cerebrovascular disease Diseases 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
VHTQQDXPNUTMNB-ONEGZZNKSA-N cis-2-hydroxypenta-2,4-dienoic acid Chemical compound OC(=O)C(\O)=C/C=C VHTQQDXPNUTMNB-ONEGZZNKSA-N 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
208000010877 cognitive disease Diseases 0.000 description 2
230000001149 cognitive effect Effects 0.000 description 2
230000009918 complex formation Effects 0.000 description 2
230000002354 daily effect Effects 0.000 description 2
231100000868 delusion Toxicity 0.000 description 2
230000003001 depressive effect Effects 0.000 description 2
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
230000003292 diminished effect Effects 0.000 description 2
239000000221 dopamine uptake inhibitor Substances 0.000 description 2
230000003291 dopaminomimetic effect Effects 0.000 description 2
230000009977 dual effect Effects 0.000 description 2
230000002996 emotional effect Effects 0.000 description 2
230000002124 endocrine Effects 0.000 description 2
201000003104 endogenous depression Diseases 0.000 description 2
238000006911 enzymatic reaction Methods 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
TZORNSWZUZDUCU-UHFFFAOYSA-N ethyl 2-methylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=CN=C1C TZORNSWZUZDUCU-UHFFFAOYSA-N 0.000 description 2
VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000003203 everyday effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000001815 facial effect Effects 0.000 description 2
206010016256 fatigue Diseases 0.000 description 2
SNJDSTGQYRTZJT-UHFFFAOYSA-N fenpentadiol Chemical compound CC(C)(O)CC(C)(O)C1=CC=C(Cl)C=C1 SNJDSTGQYRTZJT-UHFFFAOYSA-N 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000003862 glucocorticoid Substances 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
230000036541 health Effects 0.000 description 2
125000000592 heterocycloalkyl group Chemical group 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
102000043675 human DAO Human genes 0.000 description 2
150000002430 hydrocarbons Chemical group 0.000 description 2
150000001261 hydroxy acids Chemical class 0.000 description 2
206010020765 hypersomnia Diseases 0.000 description 2
210000003016 hypothalamus Anatomy 0.000 description 2
125000001841 imino group Chemical group [H]N=* 0.000 description 2
230000006698 induction Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
206010022437 insomnia Diseases 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
150000004694 iodide salts Chemical class 0.000 description 2
230000002427 irreversible effect Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
229960003136 leucine Drugs 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000007774 longterm Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
238000002483 medication Methods 0.000 description 2
SOXAGEOHPCXXIO-DVOMOZLQSA-N menthyl anthranilate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)C1=CC=CC=C1N SOXAGEOHPCXXIO-DVOMOZLQSA-N 0.000 description 2
229960002248 meradimate Drugs 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
MQONVZMIFQQQHA-UHFFFAOYSA-N methyl 3-bromo-2-oxopropanoate Chemical compound COC(=O)C(=O)CBr MQONVZMIFQQQHA-UHFFFAOYSA-N 0.000 description 2
208000005264 motor neuron disease Diseases 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
210000000653 nervous system Anatomy 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
239000002767 noradrenalin uptake inhibitor Substances 0.000 description 2
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
229960002748 norepinephrine Drugs 0.000 description 2
239000002751 oligonucleotide probe Substances 0.000 description 2
KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
208000024817 paranoid personality disease Diseases 0.000 description 2
230000007310 pathophysiology Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
208000028280 polygenic inheritance Diseases 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
RJKFOVLPORLFTN-UHFFFAOYSA-N progesterone acetate Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 RJKFOVLPORLFTN-UHFFFAOYSA-N 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000006916 protein interaction Effects 0.000 description 2
229940107700 pyruvic acid Drugs 0.000 description 2
XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
239000013037 reversible inhibitor Substances 0.000 description 2
HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 2
229960004889 salicylic acid Drugs 0.000 description 2
229930195734 saturated hydrocarbon Natural products 0.000 description 2
238000002416 scanning tunnelling spectroscopy Methods 0.000 description 2
230000000862 serotonergic effect Effects 0.000 description 2
229960000652 sertindole Drugs 0.000 description 2
GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
239000004299 sodium benzoate Substances 0.000 description 2
235000010234 sodium benzoate Nutrition 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
MQGYVGKMCRDEAF-UHFFFAOYSA-M sodium;2-oxo-3-phenylpropanoate Chemical compound [Na+].[O-]C(=O)C(=O)CC1=CC=CC=C1 MQGYVGKMCRDEAF-UHFFFAOYSA-M 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
241000894007 species Species 0.000 description 2
238000010186 staining Methods 0.000 description 2
229960001544 sulfathiazole Drugs 0.000 description 2
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
230000005062 synaptic transmission Effects 0.000 description 2
229940037128 systemic glucocorticoids Drugs 0.000 description 2
229960001367 tartaric acid Drugs 0.000 description 2
235000002906 tartaric acid Nutrition 0.000 description 2
239000011975 tartaric acid Substances 0.000 description 2
208000011317 telomere syndrome Diseases 0.000 description 2
229960002178 thiamazole Drugs 0.000 description 2
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
PNYVLXPVUIRAAO-UHFFFAOYSA-N thiomorpholine-2,6-dicarboxylic acid Chemical compound OC(=O)C1CNCC(C(O)=O)S1 PNYVLXPVUIRAAO-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
229960000607 ziprasidone Drugs 0.000 description 2
MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 1
GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
GBLRQXKSCRCLBZ-YVQAASCFSA-N (1R,2S,1'R,2'S)-doxacurium Chemical compound COC1=C(OC)C(OC)=CC(C[C@H]2[N@+](CCC3=C2C(=C(OC)C(OC)=C3)OC)(C)CCCOC(=O)CCC(=O)OCCC[N@@+]2(C)[C@@H](C3=C(OC)C(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=C(OC)C=2)=C1 GBLRQXKSCRCLBZ-YVQAASCFSA-N 0.000 description 1
IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
RILPIWOPNGRASR-UHFFFAOYSA-N (2R,3S)-2-Hydroxy-3-methylpentanoic acid Natural products CCC(C)C(O)C(O)=O RILPIWOPNGRASR-UHFFFAOYSA-N 0.000 description 1
WNNNWFKQCKFSDK-SCSAIBSYSA-N (2r)-2-azaniumylpent-4-enoate Chemical compound [O-]C(=O)[C@H]([NH3+])CC=C WNNNWFKQCKFSDK-SCSAIBSYSA-N 0.000 description 1
WHBMMWSBFZVSSR-VKHMYHEASA-N (S)-3-hydroxybutyric acid Chemical compound C[C@H](O)CC(O)=O WHBMMWSBFZVSSR-VKHMYHEASA-N 0.000 description 1
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 description 1
KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
YGTOAIKBDBKZHX-UHFFFAOYSA-N 1,4-thiazepine-3,5-dicarboxylic acid Chemical compound OC(=O)C1=CSC=CC(C(O)=O)=N1 YGTOAIKBDBKZHX-UHFFFAOYSA-N 0.000 description 1
JSQZLEYFOOSZPU-UHFFFAOYSA-N 1-[(3-carbamimidoylphenyl)methyl]-n-[(3,5-dimethylphenyl)methyl]-4-methylindole-2-carboxamide Chemical compound CC1=CC(C)=CC(CNC(=O)C=2N(C3=CC=CC(C)=C3C=2)CC=2C=C(C=CC=2)C(N)=N)=C1 JSQZLEYFOOSZPU-UHFFFAOYSA-N 0.000 description 1
XMZRJPITAOAPLJ-UHFFFAOYSA-N 1-chloro-2-nitroethane Chemical compound [O-][N+](=O)CCCl XMZRJPITAOAPLJ-UHFFFAOYSA-N 0.000 description 1
VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
FIOHTMQGSFVHEZ-UHFFFAOYSA-N 2,2'-iminodipropanoic acid Chemical compound OC(=O)C(C)NC(C)C(O)=O FIOHTMQGSFVHEZ-UHFFFAOYSA-N 0.000 description 1
PFFQEAUPDILOAV-UHFFFAOYSA-N 2,2-dihydroxy-1-phenylethanone;hydrate Chemical compound O.OC(O)C(=O)C1=CC=CC=C1 PFFQEAUPDILOAV-UHFFFAOYSA-N 0.000 description 1
WFEXVZXSHXQWAZ-UHFFFAOYSA-N 2-[(diethylazaniumyl)methyl]-6-(hydroxymethyl)-4-oxopyran-3-olate Chemical compound CCN(CC)CC=1OC(CO)=CC(=O)C=1O WFEXVZXSHXQWAZ-UHFFFAOYSA-N 0.000 description 1
VHBSECWYEFJRNV-UHFFFAOYSA-N 2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1O.OC(=O)C1=CC=CC=C1O VHBSECWYEFJRNV-UHFFFAOYSA-N 0.000 description 1
AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
YQBLQKZERMAVDO-UHFFFAOYSA-N 2-oxo-2-phenylacetaldehyde;hydrate Chemical compound O.O=CC(=O)C1=CC=CC=C1 YQBLQKZERMAVDO-UHFFFAOYSA-N 0.000 description 1
COJBGNAUUSNXHX-UHFFFAOYSA-N 2-oxoglutaramic acid Chemical compound NC(=O)CCC(=O)C(O)=O COJBGNAUUSNXHX-UHFFFAOYSA-N 0.000 description 1
ONGPAWNLFDCRJE-UHFFFAOYSA-N 2-oxosuccinamic acid Chemical compound NC(=O)CC(=O)C(O)=O ONGPAWNLFDCRJE-UHFFFAOYSA-N 0.000 description 1
WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
ZRVVGUDEOOSIQL-UHFFFAOYSA-N 3-(1H-indol-3-yl)-2-oxopropanoic acid Chemical compound C1=CC=C2C(CC(=O)C(=O)O)=CNC2=C1.C1=CC=C2C(CC(=O)C(=O)O)=CNC2=C1 ZRVVGUDEOOSIQL-UHFFFAOYSA-N 0.000 description 1
JEJNWEREQWMOHB-UHFFFAOYSA-N 3-(imidazol-5-yl)pyruvic acid Chemical compound OC(=O)C(=O)CC1=CNC=N1 JEJNWEREQWMOHB-UHFFFAOYSA-N 0.000 description 1
BXRLWGXPSRYJDZ-UHFFFAOYSA-N 3-cyanoalanine Chemical compound OC(=O)C(N)CC#N BXRLWGXPSRYJDZ-UHFFFAOYSA-N 0.000 description 1
ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
HHDDCCUIIUWNGJ-UHFFFAOYSA-N 3-hydroxypyruvic acid Chemical compound OCC(=O)C(O)=O HHDDCCUIIUWNGJ-UHFFFAOYSA-N 0.000 description 1
OJOLFAIGOXZBCI-UHFFFAOYSA-N 3-mercaptopyruvic acid Chemical compound OC(=O)C(=O)CS OJOLFAIGOXZBCI-UHFFFAOYSA-N 0.000 description 1
239000001668 3-methyl-2-oxopentanoic acid Substances 0.000 description 1
JVQYSWDUAOAHFM-UHFFFAOYSA-N 3-methyl-2-oxovaleric acid Chemical compound CCC(C)C(=O)C(O)=O JVQYSWDUAOAHFM-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
RKXDGQFOLMYFFG-UHFFFAOYSA-N 4-amino-n-(1,3-thiazol-2-yl)benzenesulfonamide;sodium Chemical compound [Na].C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 RKXDGQFOLMYFFG-UHFFFAOYSA-N 0.000 description 1
108010082309 4-hydroxybenzoate 3-monooxygenase Proteins 0.000 description 1
SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
SXFSQZDSUWACKX-UHFFFAOYSA-N 4-methylthio-2-oxobutanoic acid Chemical compound CSCCC(=O)C(O)=O SXFSQZDSUWACKX-UHFFFAOYSA-N 0.000 description 1
QPJCYJIZFCJYIR-UHFFFAOYSA-N 4-propylazetidin-2-one Chemical compound CCCC1CC(=O)N1 QPJCYJIZFCJYIR-UHFFFAOYSA-N 0.000 description 1
ZOXMLSDKXHNVOQ-UHFFFAOYSA-N 4h-1,4-thiazine Chemical compound N1C=CSC=C1 ZOXMLSDKXHNVOQ-UHFFFAOYSA-N 0.000 description 1
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
IALVDLPLCLFBCF-ZGTCLIOFSA-N 5-(methoxymethyl)-3-[4-[(3r)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-1,3-oxazolidin-2-one Chemical compound O=C1OC(COC)CN1C1=CC=C(OCC[C@@H](O)C(F)(F)F)C=C1 IALVDLPLCLFBCF-ZGTCLIOFSA-N 0.000 description 1
PQGCEDQWHSBAJP-TXICZTDVSA-N 5-O-phosphono-alpha-D-ribofuranosyl diphosphate Chemical compound O[C@H]1[C@@H](O)[C@@H](O[P@](O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O PQGCEDQWHSBAJP-TXICZTDVSA-N 0.000 description 1
QUKRTJQSGPLQKQ-UHFFFAOYSA-N 5-methylsulfonyl-3h-1,3-benzoxazol-2-one Chemical compound CS(=O)(=O)C1=CC=C2OC(=O)NC2=C1 QUKRTJQSGPLQKQ-UHFFFAOYSA-N 0.000 description 1
GWENQMVPLJAMAE-UHFFFAOYSA-N 6-amino-2-oxohexanoic acid Chemical compound [NH3+]CCCCC(=O)C([O-])=O GWENQMVPLJAMAE-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
206010050013 Abulia Diseases 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
206010001496 Agitated depression Diseases 0.000 description 1
206010001540 Akathisia Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
206010002859 Anxiety disorder due to a general medical condition Diseases 0.000 description 1
206010003805 Autism Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010006242 Breast enlargement Diseases 0.000 description 1
208000021465 Brief psychotic disease Diseases 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
KDHUHPMQUROTOM-UHFFFAOYSA-N C(CCCCCC)(=O)O.S(=O)(=O)(O)O.C(CCCCCC)(=O)O Chemical compound C(CCCCCC)(=O)O.S(=O)(=O)(O)O.C(CCCCCC)(=O)O KDHUHPMQUROTOM-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
108010089254 Cholesterol oxidase Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
206010010964 Coprolalia Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
208000024254 Delusional disease Diseases 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
206010013486 Distractibility Diseases 0.000 description 1
206010013642 Drooling Diseases 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
TWLLPUMZVVGILS-UHFFFAOYSA-N Ethyl 2-aminobenzoate Chemical compound CCOC(=O)C1=CC=CC=C1N TWLLPUMZVVGILS-UHFFFAOYSA-N 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
206010016777 Flight of ideas Diseases 0.000 description 1
PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
208000011688 Generalised anxiety disease Diseases 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
206010061991 Grimacing Diseases 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
206010018762 Grunting Diseases 0.000 description 1
241001272567 Hominoidea Species 0.000 description 1
101000609559 Homo sapiens D-aspartate oxidase Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
208000030990 Impulse-control disease Diseases 0.000 description 1
206010021567 Impulsive behaviour Diseases 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
208000037093 Menstruation Disturbances Diseases 0.000 description 1
FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
108091092878 Microsatellite Proteins 0.000 description 1
KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
ARFHIAQFJWUCFH-UHFFFAOYSA-N N-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitro-2-furanyl)methanimine Chemical compound CC1CS(=O)(=O)CCN1N=CC1=CC=C([N+]([O-])=O)O1 ARFHIAQFJWUCFH-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
UOCZTKGPJZSRIP-DGPROHSZSA-N N[C@H](CC#C)C(=O)O.N[C@@H](C(=O)O)CC#C Chemical compound N[C@H](CC#C)C(=O)O.N[C@@H](C(=O)O)CC#C UOCZTKGPJZSRIP-DGPROHSZSA-N 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
206010060860 Neurological symptom Diseases 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
SUALIQUJGJOEKT-UHFFFAOYSA-N O=CC(=O)C1=CC=CC=C1.OC(O)C(=O)C1=CC=CC=C1 Chemical compound O=CC(=O)C1=CC=CC=C1.OC(O)C(=O)C1=CC=CC=C1 SUALIQUJGJOEKT-UHFFFAOYSA-N 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
108010047386 Pituitary Hormones Proteins 0.000 description 1
102000006877 Pituitary Hormones Human genes 0.000 description 1
206010036649 Pressure of speech Diseases 0.000 description 1
206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
206010038583 Repetitive speech Diseases 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
102100035717 Serine racemase Human genes 0.000 description 1
108010006152 Serine racemase Proteins 0.000 description 1
208000008630 Sialorrhea Diseases 0.000 description 1
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
206010042008 Stereotypy Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
208000011962 Substance-induced mood disease Diseases 0.000 description 1
231100000395 Substance-induced mood disorder Toxicity 0.000 description 1
206010042458 Suicidal ideation Diseases 0.000 description 1
206010042464 Suicide attempt Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
206010064805 Tachyphrenia Diseases 0.000 description 1
206010043169 Tearfulness Diseases 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
102000011923 Thyrotropin Human genes 0.000 description 1
108010061174 Thyrotropin Proteins 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
208000021017 Weight Gain Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
125000005103 alkyl silyl group Chemical group 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
229960003036 amisulpride Drugs 0.000 description 1
NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
210000004727 amygdala Anatomy 0.000 description 1
RWZYAGGXGHYGMB-UHFFFAOYSA-M anthranilate Chemical compound NC1=CC=CC=C1C([O-])=O RWZYAGGXGHYGMB-UHFFFAOYSA-M 0.000 description 1
238000012098 association analyses Methods 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
229940127236 atypical antipsychotics Drugs 0.000 description 1
IALVDLPLCLFBCF-CHWSQXEVSA-N befloxatone Chemical compound O=C1O[C@@H](COC)CN1C1=CC=C(OCC[C@@H](O)C(F)(F)F)C=C1 IALVDLPLCLFBCF-CHWSQXEVSA-N 0.000 description 1
229950000017 befloxatone Drugs 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
239000012964 benzotriazole Substances 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000000035 biogenic effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000004397 blinking Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
229960001058 bupropion Drugs 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229940018333 calcium pyruvate Drugs 0.000 description 1
BKMMOJVSLBZNTK-UHFFFAOYSA-L calcium;2-oxo-3-phenylpropanoate Chemical compound [Ca+2].[O-]C(=O)C(=O)CC1=CC=CC=C1.[O-]C(=O)C(=O)CC1=CC=CC=C1 BKMMOJVSLBZNTK-UHFFFAOYSA-L 0.000 description 1
UZWMCCLZMHPPKW-UHFFFAOYSA-L calcium;2-oxopropanoate Chemical compound [Ca+2].CC(=O)C([O-])=O.CC(=O)C([O-])=O UZWMCCLZMHPPKW-UHFFFAOYSA-L 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
210000001159 caudate nucleus Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
229960003920 cocaine Drugs 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
238000011970 concomitant therapy Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
210000000877 corpus callosum Anatomy 0.000 description 1
229950006073 cotinine Drugs 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
229960001270 d- tartaric acid Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000007547 defect Effects 0.000 description 1
238000006356 dehydrogenation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
150000001982 diacylglycerols Chemical class 0.000 description 1
125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
150000008050 dialkyl sulfates Chemical class 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
235000001916 dieting Nutrition 0.000 description 1
230000037228 dieting effect Effects 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
229910001882 dioxygen Inorganic materials 0.000 description 1
GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
238000009826 distribution Methods 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
229940048879 dl tartaric acid Drugs 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
229940043264 dodecyl sulfate Drugs 0.000 description 1
229940052760 dopamine agonists Drugs 0.000 description 1
239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000009509 drug development Methods 0.000 description 1
238000007877 drug screening Methods 0.000 description 1
238000007878 drug screening assay Methods 0.000 description 1
206010013781 dry mouth Diseases 0.000 description 1
229960002866 duloxetine Drugs 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000001544 dysphoric effect Effects 0.000 description 1
230000007937 eating Effects 0.000 description 1
208000002161 echolalia Diseases 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
MZDOALRUOUWDRL-UHFFFAOYSA-N ethyl 2-aminobenzoate;2-(ethylamino)benzoic acid Chemical compound CCNC1=CC=CC=C1C(O)=O.CCOC(=O)C1=CC=CC=C1N MZDOALRUOUWDRL-UHFFFAOYSA-N 0.000 description 1
230000008921 facial expression Effects 0.000 description 1
229950011196 fenpentadiol Drugs 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
229960002690 fluphenazine Drugs 0.000 description 1
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
229960004038 fluvoxamine Drugs 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
208000029364 generalized anxiety disease Diseases 0.000 description 1
102000054766 genetic haplotypes Human genes 0.000 description 1
230000008303 genetic mechanism Effects 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
125000003147 glycosyl group Chemical group 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
230000021061 grooming behavior Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
239000000380 hallucinogen Substances 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
BICAGYDGRXJYGD-UHFFFAOYSA-N hydrobromide;hydrochloride Chemical compound Cl.Br BICAGYDGRXJYGD-UHFFFAOYSA-N 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
230000001505 hypomanic effect Effects 0.000 description 1
239000000960 hypophysis hormone Substances 0.000 description 1
230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
229960003162 iloperidone Drugs 0.000 description 1
XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000002621 immunoprecipitating effect Effects 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
230000005032 impulse control Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
208000022119 inability to concentrate Diseases 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
OLNJUISKUQQNIM-UHFFFAOYSA-N indole-3-carbaldehyde Chemical group C1=CC=C2C(C=O)=CNC2=C1 OLNJUISKUQQNIM-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
NBKQRVSGHYZUOR-UHFFFAOYSA-N indoline-3-carbaldehyde Chemical group C1=CC=C2C(C=O)CNC2=C1 NBKQRVSGHYZUOR-UHFFFAOYSA-N 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
208000021005 inheritance pattern Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000012482 interaction analysis Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
229960002589 iproclozide Drugs 0.000 description 1
GGECDTUJZOXAAR-UHFFFAOYSA-N iproclozide Chemical compound CC(C)NNC(=O)COC1=CC=C(Cl)C=C1 GGECDTUJZOXAAR-UHFFFAOYSA-N 0.000 description 1
229940070023 iproniazide Drugs 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
238000005304 joining Methods 0.000 description 1
230000009191 jumping Effects 0.000 description 1
150000004715 keto acids Chemical class 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
229940116298 l- malic acid Drugs 0.000 description 1
BRHPBVXVOVMTIQ-ZLELNMGESA-N l-leucine l-leucine Chemical compound CC(C)C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O BRHPBVXVOVMTIQ-ZLELNMGESA-N 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
BKPLVPRTTWIDNL-ZIAGYGMSSA-N levofacetoperane Chemical compound C([C@@H]1[C@H](OC(=O)C)C=2C=CC=CC=2)CCCN1 BKPLVPRTTWIDNL-ZIAGYGMSSA-N 0.000 description 1
229950004771 levofacetoperane Drugs 0.000 description 1
125000003473 lipid group Chemical group 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
238000007449 liver function test Methods 0.000 description 1
230000003137 locomotive effect Effects 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000021121 meiosis Effects 0.000 description 1
231100000544 menstrual irregularity Toxicity 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
230000004630 mental health Effects 0.000 description 1
125000005358 mercaptoalkyl group Chemical group 0.000 description 1
XUTLZGKVFSLSDR-UHFFFAOYSA-N methyl 2-oxopropanoate;2-oxobutanoic acid Chemical compound CCC(=O)C(O)=O.COC(=O)C(C)=O XUTLZGKVFSLSDR-UHFFFAOYSA-N 0.000 description 1
RMNJNEUWTBBZPT-UHFFFAOYSA-N methyl 4-nitrobenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 RMNJNEUWTBBZPT-UHFFFAOYSA-N 0.000 description 1
UZGZDEIWPDOQPB-UHFFFAOYSA-N methyl 4-nitrobenzenesulfonate 2-methyl-4-nitrobenzenesulfonic acid Chemical compound COS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1.CC1=CC([N+]([O-])=O)=CC=C1S(O)(=O)=O UZGZDEIWPDOQPB-UHFFFAOYSA-N 0.000 description 1
QVDXUKJJGUSGLS-LURJTMIESA-N methyl L-leucinate Chemical compound COC(=O)[C@@H](N)CC(C)C QVDXUKJJGUSGLS-LURJTMIESA-N 0.000 description 1
QFVDKARCPMTZCS-UHFFFAOYSA-N methylrosaniline Chemical compound C1=CC(N(C)C)=CC=C1C(O)(C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 QFVDKARCPMTZCS-UHFFFAOYSA-N 0.000 description 1
229960002545 methylthiouracil Drugs 0.000 description 1
229960000600 milnacipran Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229960004938 molindone Drugs 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000010082 neurochemical mechanism Effects 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
230000003957 neurotransmitter release Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
208000005346 nocturnal enuresis Diseases 0.000 description 1
230000000966 norepinephrine reuptake Effects 0.000 description 1
229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
KXFJZKUFXHWWAJ-UHFFFAOYSA-N p-hydroxybenzoylformic acid Natural products OC(=O)C(=O)C1=CC=C(O)C=C1 KXFJZKUFXHWWAJ-UHFFFAOYSA-N 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
208000002851 paranoid schizophrenia Diseases 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
HVAMZGADVCBITI-UHFFFAOYSA-N pent-4-enoic acid Chemical compound OC(=O)CCC=C HVAMZGADVCBITI-UHFFFAOYSA-N 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
229960000762 perphenazine Drugs 0.000 description 1
208000022821 personality disease Diseases 0.000 description 1
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
229950010883 phencyclidine Drugs 0.000 description 1
229960000964 phenelzine Drugs 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
229960003890 pimagedine Drugs 0.000 description 1
YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
229960003634 pimozide Drugs 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
208000028173 post-traumatic stress disease Diseases 0.000 description 1
KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 description 1
FRMWBRPWYBNAFB-UHFFFAOYSA-M potassium salicylate Chemical compound [K+].OC1=CC=CC=C1C([O-])=O FRMWBRPWYBNAFB-UHFFFAOYSA-M 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000001472 potassium tartrate Substances 0.000 description 1
229940111695 potassium tartrate Drugs 0.000 description 1
235000011005 potassium tartrates Nutrition 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000003196 psychodysleptic agent Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
235000008160 pyridoxine Nutrition 0.000 description 1
239000011677 pyridoxine Substances 0.000 description 1
125000002181 pyridoxine group Chemical group 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
238000011002 quantification Methods 0.000 description 1
229960004431 quetiapine Drugs 0.000 description 1
URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
235000019192 riboflavin Nutrition 0.000 description 1
239000002151 riboflavin Substances 0.000 description 1
229960002477 riboflavin Drugs 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
229950005741 rolipram Drugs 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229940035004 seroquel Drugs 0.000 description 1
230000000697 serotonin reuptake Effects 0.000 description 1
239000003772 serotonin uptake inhibitor Substances 0.000 description 1
230000004905 short-term response Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000007958 sleep Effects 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
YGSPWCVTJRFZEL-UHFFFAOYSA-M sodium;2-(1h-indol-3-yl)acetate Chemical compound [Na+].C1=CC=C2C(CC(=O)[O-])=CNC2=C1 YGSPWCVTJRFZEL-UHFFFAOYSA-M 0.000 description 1
MOSCXNXKSOHVSQ-UHFFFAOYSA-M sodium;2-hydroxybutanoate Chemical compound [Na+].CCC(O)C([O-])=O MOSCXNXKSOHVSQ-UHFFFAOYSA-M 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
201000006152 substance dependence Diseases 0.000 description 1
210000003523 substantia nigra Anatomy 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
210000001103 thalamus Anatomy 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
229960002784 thioridazine Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
208000027100 transient tic disease Diseases 0.000 description 1
238000013519 translation Methods 0.000 description 1
229960003741 tranylcypromine Drugs 0.000 description 1
230000008733 trauma Effects 0.000 description 1
150000003852 triazoles Chemical class 0.000 description 1
ZMCBYSBVJIMENC-UHFFFAOYSA-N tricaine Chemical compound CCOC(=O)C1=CC=CC(N)=C1 ZMCBYSBVJIMENC-UHFFFAOYSA-N 0.000 description 1
ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
229960002324 trifluoperazine Drugs 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
239000004474 valine Substances 0.000 description 1
229960004295 valine Drugs 0.000 description 1
238000012795 verification Methods 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
229940011671 vitamin b6 Drugs 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
230000002618 waking effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1
QWZIITCYKKSZGN-UHFFFAOYSA-N xi-3-Hydroxy-2-oxobutanoic acid Chemical compound CC(O)C(=O)C(O)=O QWZIITCYKKSZGN-UHFFFAOYSA-N 0.000 description 1
229960004496 zotepine Drugs 0.000 description 1
HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)
Urology & Nephrology (AREA)
Physics & Mathematics (AREA)
Psychiatry (AREA)
Cell Biology (AREA)
General Engineering & Computer Science (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Toxicology (AREA)

CA002433866A 2001-01-16 2002-01-15 Traitement de troubles du systeme nerveux central au moyen d'antagonistes de la d-amino acide oxydase et de la d-aspartate oxydase Abandoned CA2433866A1 (fr)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US26188301P	2001-01-16	2001-01-16
US60/261,883		2001-01-16
US30544501P	2001-07-13	2001-07-13
US60/305,445		2001-07-13
US34521101P	2001-10-22	2001-10-22
US60/345,211		2001-10-22
US33388101P	2001-11-19	2001-11-19
US60/333,881		2001-11-19
PCT/IB2002/001262 WO2002066672A2 (fr)	2001-01-16	2002-01-15	Traitement de troubles du systeme nerveux central au moyen d'antagonistes de la d-amino acide oxydase et de la d-aspartate oxydase

Publications (1)

Publication Number	Publication Date
CA2433866A1 true CA2433866A1 (fr)	2002-08-29

Family

ID=27500728

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002433866A Abandoned CA2433866A1 (fr)	2001-01-16	2002-01-15	Traitement de troubles du systeme nerveux central au moyen d'antagonistes de la d-amino acide oxydase et de la d-aspartate oxydase

Country Status (11)

Country	Link
EP (1)	EP1412515A2 (fr)
JP (1)	JP2004537275A (fr)
KR (1)	KR20030066813A (fr)
CN (1)	CN1568370A (fr)
AU (1)	AU2002247939B2 (fr)
BR (1)	BR0206495A (fr)
CA (1)	CA2433866A1 (fr)
EA (1)	EA006654B1 (fr)
IL (1)	IL156865A0 (fr)
MX (1)	MXPA03006321A (fr)
WO (1)	WO2002066672A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030013846A1 (en)	2001-05-03	2003-01-16	Bing Wang	Pyruvate derivatives
WO2003070743A1 (fr) *	2002-02-20	2003-08-28	Ribozyme Pharmaceuticals, Inc.	Inhibition de l'expression genique de g72 et de la d-amino acide oxydase (daao) induite par l'interference d'arn au moyen d'un acide nucleique interferant court (nasi)
EP1291015A1 (fr)	2001-09-10	2003-03-12	Lunamed AG	Compositions à libération prolongée d'un agent actif
US20030162825A1 (en) *	2001-11-09	2003-08-28	Sepracor Inc.	D-amino acid oxidase inhibitors for learning and memory
WO2003047558A2 (fr) *	2001-12-03	2003-06-12	Genset S.A.	Traitement de troubles du systeme nerveux central a l'aide d'inhibiteurs de d-amino-oxydase et de d-aspartate oxydase
EP1451349A2 (fr) *	2001-12-12	2004-09-01	Genset	Marqueurs bialleliques de diamine oxydase et ses utilisations
GB0223424D0 (en) *	2002-10-09	2002-11-13	Imp College Innovations Ltd	Disease-associated gene
CA2551952A1 (fr)	2003-12-29	2005-07-21	Sepracor Inc.	Inhibiteurs daao de pyrrole et de pyrazole
WO2007082208A2 (fr) *	2006-01-09	2007-07-19	Oklahoma Medical Research Foundation	Composés apparentés à la lanthionine pour le traitement de maladies inflammatoires
US7884124B2 (en)	2006-06-30	2011-02-08	Sepracor Inc.	Fluoro-substituted inhibitors of D-amino acid oxidase
US7902252B2 (en) *	2007-01-18	2011-03-08	Sepracor, Inc.	Inhibitors of D-amino acid oxidase
GB2456390A (en) *	2008-01-15	2009-07-22	Glaxo Group Ltd	Bipolar disorder treatments
CA2750028C (fr)	2009-01-20	2019-05-07	Guochuan Emil Tsai	Acide sorbique et benzoique et derives de celui-ci pour ameliorer l'activite d'un produit neuropharmaceutique
JP4462382B1 (ja) *	2009-04-23	2010-05-12	学校法人北里研究所	Ｄ−アスパラギン酸オキシダーゼおよびｄ−アミノ酸オキシダーゼに対する新規阻害剤
WO2012135119A1 (fr) *	2011-03-25	2012-10-04	Genomind, Llc	Détection fondée sur un biomarqueur et traitement de la dépression neurodégénérative
WO2013148260A1 (fr)	2012-03-30	2013-10-03	Washington University	Procédés de modulation de l'expression de tau pour réduire l'avc et modifier un symptôme neurodégénératif
TW202246503A (zh)	2013-07-19	2022-12-01	美商百健Ｍａ公司	用於調節τ蛋白表現之組合物
CN109563018A (zh)	2016-06-13	2019-04-02	心悦生医股份有限公司	苯甲酸钠的共晶及其用途
CN109563024B (zh)	2016-06-13	2023-06-06	心悦生医股份有限公司	苯甲酸锂的共晶及其用途
US10336679B2 (en)	2016-10-24	2019-07-02	Syneurx International (Taiwan) Corp.	Polymorphic forms of sodium benzoate and uses thereof
US11369579B2 (en)	2016-10-24	2022-06-28	Syneurx International (Taiwan) Corp.	Polymorphic forms of sodium benzoate and uses thereof
US10098861B1 (en)	2017-10-24	2018-10-16	Syneurx International (Taiwan) Corp.	Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof
CN108504752B (zh) *	2018-06-26	2021-05-11	华中农业大学	一种与母猪繁殖性状关联的分子标记及应用
CN111909907B (zh) *	2020-07-08	2022-05-24	浙江工业大学	天冬氨酸氧化酶突变体、工程菌及其在氧化-还原偶联制备精草铵膦中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5668117A (en) *	1991-02-22	1997-09-16	Shapiro; Howard K.	Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
EP1165836A2 (fr) *	1999-03-30	2002-01-02	Genset	Genes, proteines, et marqueurs bialleliques associes a la schizophrenie
AU6462500A (en) *	1999-07-29	2001-02-19	Patrick T. Prendergast	Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2001068104A1 (fr) *	2000-03-16	2001-09-20	The Mclean Hospital Corporation	Composes servant a traiter des troubles psychiatriques ou des troubles provoques par la consommation abusive de substances psychoactives

2002
- 2002-01-15 EP EP02717019A patent/EP1412515A2/fr not_active Withdrawn
- 2002-01-15 BR BR0206495-2A patent/BR0206495A/pt not_active IP Right Cessation
- 2002-01-15 CN CNA028066650A patent/CN1568370A/zh active Pending
- 2002-01-15 AU AU2002247939A patent/AU2002247939B2/en not_active Ceased
- 2002-01-15 CA CA002433866A patent/CA2433866A1/fr not_active Abandoned
- 2002-01-15 WO PCT/IB2002/001262 patent/WO2002066672A2/fr not_active Ceased
- 2002-01-15 IL IL15686502A patent/IL156865A0/xx unknown
- 2002-01-15 EA EA200300807A patent/EA006654B1/ru not_active IP Right Cessation
- 2002-01-15 MX MXPA03006321A patent/MXPA03006321A/es unknown
- 2002-01-15 JP JP2002566376A patent/JP2004537275A/ja active Pending
- 2002-01-15 KR KR10-2003-7009412A patent/KR20030066813A/ko not_active Ceased

Also Published As

Publication number	Publication date
BR0206495A (pt)	2006-01-24
AU2002247939B2 (en)	2007-01-25
AU2002247939B9 (en)	2002-09-04
IL156865A0 (en)	2004-02-08
JP2004537275A (ja)	2004-12-16
KR20030066813A (ko)	2003-08-09
MXPA03006321A (es)	2003-10-06
WO2002066672A3 (fr)	2004-02-26
WO2002066672A2 (fr)	2002-08-29
EA200300807A1 (ru)	2004-08-26
EP1412515A2 (fr)	2004-04-28
CN1568370A (zh)	2005-01-19
EA006654B1 (ru)	2006-02-24

Publication	Publication Date	Title
CA2433866A1 (fr)	2002-08-29	Traitement de troubles du systeme nerveux central au moyen d'antagonistes de la d-amino acide oxydase et de la d-aspartate oxydase
US20030185754A1 (en)	2003-10-02	Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
Nurmi et al.	2000	Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F] CFT
Blakely et al.	2012	MPV17 mutation causes neuropathy and leukoencephalopathy with multiple mtDNA deletions in muscle
Hirose et al.	2000	A novel mutation of KCNQ3 (c. 925T→ C) in a Japanese family with benign familial neonatal convulsions
CN107602690B (zh)	2020-10-20	肺动脉高压相关的ptgis基因突变及其应用
AU2002247939A1 (en)	2003-02-27	Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
Chen et al.	1993	Antibodies to glutamic acid decarboxylase in Australian children with insulin-dependent diabetes mellitus and their first-degree relatives
US20030166554A1 (en)	2003-09-04	Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
WO2006116873A1 (fr)	2006-11-09	Diagnostic et traitement de l'endometriose
Vallat et al.	2000	Myelin widenings and MGUS‐IgA: an immunoelectron microscopic study
Di Blasi et al.	2000	Partial laminin α2 chain deficiency in a patient with myopathy resembling inclusion body myositis
US6248528B1 (en)	2001-06-19	Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
WO1997018230A1 (fr)	1997-05-22	CLONAGE ET EXPRESSION DU RECEPTEUR DE βAPP-C100 (C100-R)
Berg et al.	2000	Changes of copper‐transporting proteins and ceruloplasmin in the lentiform nuclei in primary adult‐onset dystonia
US6368797B1 (en)	2002-04-09	Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant GPIIIa and/or variant BPIIb allele
AU2002339698B2 (en)	2007-08-23	Biallelic markers of D-amino acid oxidase and uses thereof
EP1767638A2 (fr)	2007-03-28	Mutation associee a l'epilepsie
Mayatepek	2000	Leukotriene C4 synthesis deficiency: a member of a probably underdiagnosed new group of neurometabolic diseases
Satoi et al.	2000	Decreased cerebrospinal fluid levels of β‐phenylethylamine in patients with Rett syndrome
HK1072445A (en)	2005-08-26	Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
Fujioka et al.	2001	Molecular characterisation of glutamate dehydrogenase gene defects in Japanese patients with congenital hyperinsulinism/hyperammonaemia
Eggers et al.	2000	Rapid clearance of human immunodeficiency virus type 1 from ventricular cerebrospinal fluid during antiretroviral treatment
US6323244B1 (en)	2001-11-27	Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
WO2009037481A1 (fr)	2009-03-26	Procédés permettant de diagnostiquer et de traiter la démence

Legal Events

Date	Code	Title	Description
2007-01-02	EEER	Examination request
2010-01-15	FZDE	Discontinued